GlaxoSmithKline (GSK) is running an observational study called “NUCALA® Subcutaneous Injection Special Drug Use Investigation (EGPA, Long-term)” to track how its drug Nucala performs in everyday use ...
Nucala is the only approved biologic studied in a wide COPD population with an eosinophilic phenotype characterized by blood eosinophil count (BEC) starting at 150 cells/μL Approval based on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results